Evidence map›Paper›PMID 40569061›Full record

ArticlemBio2025

Novel

Mohammed N Amin, James E Sinclair, Brittany Curtis, Lada Sycheva, Heather Fox, Myeong-Jin Choi, Surekha Shridhar, Jacqueline Kolasny, Joseph Nkeze, Ethel Apolinario and 16 more

Abstract read
In one paragraph

Article in mBio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Mohammed N AminCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
James E SinclairCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Brittany CurtisCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Lada SychevaAffinivax Inc. (a GSK company), Cambridge, Massachusetts, USA.
Heather FoxCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Myeong-Jin ChoiCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Surekha ShridharCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Jacqueline KolasnyCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Joseph NkezeCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Ethel ApolinarioCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Sang HyunCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Nicolas HegerleCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Shaichi SenCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Jasnehta Permala BoothCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Mark LeneyRRD International, Rockville, Maryland, USA.
Deborah MolrineNosocomial Vaccines Company, Rockville, Maryland, USA.
Greg SaiaNosocomial Vaccines Company, Rockville, Maryland, USA.
Marcela PasettiCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0003-0894-4009
Teresa BroeringAffinivax Inc. (a GSK company), Cambridge, Massachusetts, USA.
Francis MichonNosocomial Vaccines Company, Rockville, Maryland, USA.
Richard MalleyAffinivax Inc. (a GSK company), Cambridge, Massachusetts, USA.ORCID 0000-0002-8688-3398
George R SiberSiber Biotechnologies LLC, New York, New York, USA.
Sharon M TennantCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0002-0651-5748
Donna AmbrosinoNosocomial Vaccines Company, Rockville, Maryland, USA.
Raphael SimonCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Alan CrossCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0003-4362-9936

Funding

Astellas Pharma
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Bacterial ProteinsBacterial VaccinesKlebsiella InfectionsKlebsiella pneumoniaeO AntigensPolysaccharides, BacterialPseudomonas aeruginosaPseudomonas InfectionsPseudomonas VaccinesAnimalsAntibodies, BacterialAntigens, BacterialFemaleMiceRabbitsVirulence FactorsAntibodies, BacterialAntigens, BacterialBacterial ProteinsBacterial VaccinesO AntigensPolysaccharides, BacterialPseudomonas VaccinesVirulence FactorsflagellinKlebsiella pneumoniaeMAPS vaccineMrkAO polysaccharidePcrVPseudomonas aeruginosa

Identifiers

PMID40569061
PMCPMC12345170

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.